Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies

NCT05653271 is registered in ClinicalTrials.gov with Acepodia Biotech, Inc. as lead sponsor.

NCT NCT05653271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05653271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic Anti-CD20 Antibody-Conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies
Lead sponsor
Acepodia Biotech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 21, 2023
Completion date
March 31, 2026
Enrollment
16 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, burkitt lymphoma, dlbcl, follicular lymphoma, high-grade b-cell lymphoma, marginal zone lymphoma, non hodgkin lymphoma, primary mediastinal large b cell lymphoma